People on the Move: Specialty Pharma Companies

, , , ,


Jeffrey A. Meckler has been named as CEO of Intec Pharma Ltd. Meckler was named vice chairman of the Intec Pharma board of directors in April 2017 and will continue in that role. Giora Carni, a director since 2006 who has served as interim CEO since May 2017, will continue to serve on the company’s board. Intec Pharma is focused on developing drugs based on the company’s proprietary Accordion Pill platform technology.

Dr. Daniel Jorgensen was appointed chief medical officer and Dr. Rasappa Arumugham is now VP, research and development, at Ocugen Inc. Dr. Jorgensen is an accomplished physician executive with approximately 20 years of experience in the biopharmaceutical industry, in both small and large companies, including 10 years at Pfizer. Dr. Arumugham previously served as the head of Microbial Analytics at Merck’s manufacturing division. Ocugen is a biopharmaceutical company developing treatments for sight-threatening diseases.

Dr. Simon Bruce was named VP of Medical Affairs at Oramed Pharmaceuticals Inc. Dr. Bruce is trained in Internal Medicine with sub-specialization in Endocrinology at the National Institutes of Health (NIH). Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.

Raffi Asadorian is appointed chief financial officer of AcelRx Pharmaceuticals Inc. Asadorian brings more than 25 years of finance, strategy and corporate development experience to AcelRx, most recently as chief financial officer at Amyris, a commercial-stage biotechnology company. AcelRx Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain.

David Beadle has become chief business officer of Peptinnovate, a drug development company developing a ‘first in class’ immune regulating therapy for asthma. Beadle was at UBS AG investment bank where he was a managing director in the equities division.

Eleanor L. Ramos, M.D., is now chief medical officer and chief operating officer of Provention Bio Inc. Dr. Ramos joins Provention after most recently serving as a chief medical officer of Global Blood Therapeutics. Provention Bio is a clinical-stage biopharmaceutical company dedicated to sourcing, developing, and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated disease.

Samuel H. Israel was appointed VP, chief legal officer and general counsel of Lannett Company Inc. Prior to joining Lannett, Israel was a partner with Fox Rothschild, a national, full-service law firm, serving as chair of the firm’s Pharmaceutical and Biotechnology Practice. Lannett develops, manufactures, packages, markets and distributes generic pharmaceutical products.